Singapore Earns WHO's Top Medical Device Safety Rating

Singapore's Health Sciences Authority (HSA) has made history as the first national regulator to reach the World Health Organization's highest level for medical device safety standards.

Health Minister Ong Ye Kung announced the achievement on March 10 while unveiling updated healthcare AI guidelines designed to speed innovation without compromising patient safety. The recognition establishes Singapore as a trusted global reference point that other countries can rely on when approving medical devices and treatments.

The revised AI framework introduces regulatory sandboxes where artificial intelligence healthcare solutions can be tested in real clinical settings. This approach ensures AI tools learn from quality, real-world patient data while maintaining strict safety standards.

HSA is also preparing to review applications for AI-developed drugs, which use simulated laboratory data instead of costly traditional clinical trials. The authority promises to apply the same rigorous standards to these innovative treatments as it does to conventional medications.

The Ripple Effect

Singapore's regulatory excellence is already benefiting patients far beyond its borders. Countries including Australia, Malaysia, the Philippines, Thailand, Switzerland and the United Kingdom now use HSA approvals to fast-track their own regulatory processes for medical products.

The island nation has also joined an exclusive consortium with Australia, Canada, Switzerland and the UK to approve new therapeutic products. This partnership gives Singapore-approved innovations access to hundreds of millions of people across multiple markets.

Minister Ong emphasized that Singapore has transformed from a standalone market of six million people into a gateway serving vast international populations. The country achieved similar top-tier WHO recognition for its medicine regulatory system back in 2022.

HSA Chief Executive Raymond Chua said the authority is expanding its role to actively support Singapore's biomedical sector growth. The agency will partner with universities, hospitals and research institutions to strengthen the innovation pipeline and increase clinical trials.

Singapore plans to consolidate various healthcare regulatory functions to better support its rapidly evolving medical technology sector, particularly in AI, precision medicine and next-generation diagnostics. This patient-first approach proves that countries can embrace cutting-edge innovation while maintaining world-class safety standards that protect people's health.